Haplotype-Based Banking of Human Pluripotent Stem Cells for Transplantation: Potential and Limitations
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
High expectations surround the area of stem cells therapeutics. However, the cells' source-adult or embryonic-and the cells' origin-patient-derived autologous or healthy donor genetically unrelated-remain subjects of debate. Autologous origins have the advantage of a theoretical absence of immune rejection by the recipient. However, this approach has several limitations with regard to the disease of the recipient and to potential problems with the generation, expansion, and manipulation of autologous induced pluripotent stem cells (iPS cells) preparation. An alternative to using autologous cells is the establishment of a bank of well-characterized adult cells that would be used to generate iPS cells and their derivatives. In the context of transplantation, such cells would come from genetically unrelated donors and the immune system of the recipient would reject the graft without immunosuppressive therapy. To minimize the risk of rejection, human leukocyte antigen (HLA) compatibility is certainly the best option, and the establishment of an HLA-organized bank would mean having a limited number of stem cells that would be sufficient for a large number of recipients. The concept of haplobanking with HLA homozygous cell lines would also limit the number of HLA mismatches, but such an approach will not necessarily be less immunogenic in terms of selection criteria, because of the limited number of HLA-compatible loci and the level of HLA typing resolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, L. C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., Lynch, C., Harness, J. V., Lee, S., Barrero, M. J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2010.12.003 · Cited by 890 · cited 1×
“Recent publications have indicated that iPS cells show a high risk of chromosomal and mitochondrial DNA mutations, the chromosomal mutations were observed frequently at locations highly enhancing the probability of tumor formation [32,33].”
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402 · cited 1×
“This hypothesis seemed confirmed by the very low expression of HLA class I antigens (which appeared only weakly increased through differentiation), and by the lack of expression of HLA class II [14,15].”
Nakajima, F., Tokunaga, K., & Nakatsuji, N. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0566 · Cited by 168 · cited 2×
“This was reiterated in the study by Nakajima et al. [50] where it was suggested that 55 randomly selected homozygous embryos could produce lines to provide a perfect match for 80% of the population.”
Cited by
Stem cells in retinal regeneration: past, present and future
Ramsden, C. M., Powner, M. B., Carr, A.-J. F., Smart, M. J. K., da Cruz, L., & Coffey, P. J. (2013) · Development · doi:10.1242/dev.092270 · Cited by 253
Good Cell Culture Practice for stem cells and stem-cell-derived models
Pamies, D. (2016) · ALTEX · doi:10.14573/altex.1607121 · Cited by 160
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Metadata
- Authors
- Zimmermann, A., Preynat-Seauve, O., Tiercy, J.-M., Krause, K.-H., & Villard, J.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2012-09
- Volume
- 21
- Issue
- 13
- Pages
- 2364-2373
- ISSN
- 1525-8165 (ISSN-L)
- 1547-3287
- 1557-8534
- OpenAlex
- W1964302348
- Cited by
- 62
- References
- 3
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.